Treatment of diabetes is associated with a reduction in both macro- and microvascular complications. Macrovascular complications include myocardial infarction and stroke. One of the goals of therapy for patients with type 2 diabetes mellitus is a reduction in hemoglobin A1c (HbA1c). The goal or target HgbA1c is individualized for patients based on the presence of comorbidities, among other factors. Cardiovascular disease (CVD), when present, may influence an individual’s HbA1c goal. This blog will review the data surrounding the HbA1c goal in those with type II diabetes and established CVD.
Significant focus has been placed on the cardiovascular effects of various treatment options for type 2 diabetes. One topic of concern is the risk of heart failure (HF) associated with dipeptidyl peptidase-4 (DPP-4) inhibitors. This piece reviews the literature on DDP-4 inhibitor therapy and the risk of HF and HF hospitalization. Suggestions on how to apply the literature to practice are also provided.